More patients with ovarian cancer are receiving chemotherapy before surgery

May 30, 2014

CHICAGO, IL (May 30, 2014)--The use of chemotherapy before surgery to remove ovarian cancer has increased dramatically in recent decades, particularly among certain patients, according to a new analysis from Fox Chase Cancer Center that will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

Looking back at medical records from more than 58,000 women, Fox Chase's Angela Jain, MD, Medical Oncologist and co-investigator Elizabeth Handorf, PhD, member of the Biostatistics and Bioinformatics Facility, found that only 8.94% received chemotherapy before ovarian cancer surgery in 1998; by 2011, that figure had increased to 26.72%.

The standard of care, Dr. Jain explained, is to offer chemotherapy after surgery, not before - but in some cases, patients are not well enough to have surgery right away. "They may have other health problems, such as heart failure or severe lung disease, which complicate the procedure," she said. Their cancer may also be so far advanced that they need an additional treatment step.

Indeed, Drs. Jain and Handorf found that patients were more likely to receive so-called "neoadjuvant" chemotherapy if they were older than 70, and had additional illnesses.

Having government-run health insurance - Medicaid or Medicare - also increased a woman's odds of undergoing chemotherapy before surgery. In contrast, race and location did not appear to influence her likelihood of receiving neoadjuvant therapy.

Not surprisingly, patients who did not receive chemotherapy before surgery tended to live longer following surgery to remove their tumor - half were alive 41 months later, while median survival for those who had neoadjuvant chemotherapy was closer to 31 months. This is not an indication that neoadjuvant chemotherapy is not effective, Dr. Jain cautioned, since the women who received it were older and sicker to begin with. But additional analyses showed that patients with stage 4 disease who received neoadjuvant chemotherapy tended to have fewer complications after surgery and survive just as long as other stage 4 women. However, those with stage 3 disease tended to survive longer if they skipped neoadjuvant therapy.

Indeed, the current study cannot determine whether neoadjuvant chemotherapy was beneficial, said Dr. Jain, because it does not compare groups of similar women who were randomly chosen to receive the treatment or not. "This is good information," said Dr. Jain. "Women with stage 4 disease maybe can have chemotherapy before surgery, and their survival isn't limited. But we need to study this population in more depth before we can conclude whether there are some groups of women who should or should not be receiving neoadjuvant chemotherapy."

In the meantime, women with ovarian, fallopian, and primary peritoneal cancers who want to learn more about neoadjuvant chemotherapy should consult their physicians, said Dr. Jain. "Patients with these cancers need to talk to their oncologists about their treatment plan, and what is right for them. Each person is an individual, so their care has to be catered to them."

Just why the rate of neoadjuvant chemotherapy has increased so dramatically in ovarian cancer is "hard to know," she noted, because there are no set criteria for prescribing it. "It's a judgment call of the oncologist to decide if a patient is healthy enough to have surgery or not, and whether the gynecologic oncologist feels that they can remove all of the tumor during surgery" she said. "What we do know, is that patients in general are aging, and older patients are more likely to both have additional illnesses and receive neoadjuvant chemotherapy. So it's possible this factor may help explain why more women are receiving neoadjuvant chemotherapy."

To assess this trend, Drs. Jain and Handorf reviewed the records of 58,048 women with advanced stage ovarian cancer diagnosed between 1998 and 2011 using the National Cancer Database.
-end-
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation's first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet status for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, visit Fox Chase's Web site at http://www.foxchase.org or call 1-888-FOX CHASE or (1-888-369-2427).

Fox Chase Cancer Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.